BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2060 related articles for article (PubMed ID: 20965464)

  • 21. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
    Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
    JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
    Ong AT; Serruys PW; Aoki J; Hoye A; van Mieghem CA; Rodriguez-Granillo GA; Valgimigli M; Sonnenschein K; Regar E; van der Ent M; de Jaegere PP; McFadden EP; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT
    J Am Coll Cardiol; 2005 Apr; 45(7):1135-41. PubMed ID: 15808774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Girasis C; Piazza N; Garcia-Garcia HM; Kukreja N; Garg S; Eindhoven J; Cheng JM; Valgimigli M; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2010 Jun; 3(6):584-94. PubMed ID: 20630451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
    Kukreja N; Onuma Y; Garcia-Garcia HM; Daemen J; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    Daemen J; Tanimoto S; García-García HM; Kukreja N; van de Sande M; Sianos G; de Jaegere PP; van Domburg RT; Serruys PW
    Am J Cardiol; 2007 Apr; 99(8):1027-32. PubMed ID: 17437722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
    Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
    JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
    Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
    JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129).
    Daemen J; van Twisk PH; Kukreja N; van Domburg RT; Boersma E; de Jaegere P; Serruys PW
    EuroIntervention; 2009 Jan; 4(4):464-74. PubMed ID: 19284068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 103.